Sangamo Therapeutics Up 17%; Unveiled Updated Study Data
July 08 2019 - 8:43AM
Dow Jones News
By Michael Dabaie
Sangamo Therapeutics Inc. (SGMO) shares rose 17% to $13.37
premarket Monday.
The company and Pfizer Inc. (PFE) Friday unveiled updated
results from the Phase 1/2 Alta study evaluating investigational
SB-525 gene therapy for severe hemophilia A. The data showed that
SB-525 was generally well-tolerated and demonstrated a
dose-dependent increase in Factor VIII activity levels.
The first two patients treated at the 3e13 vg/kg dose rapidly
achieved normal levels of FVIII activity as measured using a
chromogenic assay, with no reported bleeding events, and the
response continues to be durable for as long as 24 weeks, the
extent of follow-up. The two patients more recently treated at the
3e13 vg/kg dose level are demonstrating FVIII activity kinetics
that appear consistent with the first two patients treated in this
dose cohort at similar early time points, the companies said.
SB-525 showed dose-dependent increases in FVIII activity levels
across all dose cohorts evaluated, the companies said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 08, 2019 08:28 ET (12:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Sep 2023 to Sep 2024